Sickle Cell Anemia



Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Ilaris, Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified November 2016


SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Hydroxyurea;   Procedure: TCD examination
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Hospital Infantil Dr. Robert Reid Cabral
Recruiting - verified August 2016


The Role of Endothelin-1 in Sickle Cell Disease


Condition:   Sickle Cell Anemia
Interventions:   Drug: Ambrisentan;   Drug: Placebo
Sponsors:   Augusta University;   Gilead Sciences;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016


Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease


Condition:   Sickle Cell Anemia
Intervention:  
Sponsor:   Albert Einstein College of Medicine, Inc.
Recruiting - verified July 2016


Gene Transfer for Patients With Sickle Cell Disease


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Intervention:   Genetic: Gene transfer
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Doris Duke Charitable Foundation
Recruiting - verified March 2017


Study of Beet Juice for Patients With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Intervention:   Drug: beet juice (Unbeetable)
Sponsors:   Daniel Kim-Shapiro;   Wake Forest University;   National Heart, Lung, and Blood Institute (NHLBI)
Suspended - verified March 2017


Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Intervention:   Drug: hydroxyurea
Sponsors:   Loyola University;   University of Illinois at Chicago;   University of Ibadan
Active, not recruiting - verified March 2017


Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia


Condition:   Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions:   Drug: Montelukast added to Hydroxyurea;   Drug: Placebo added to Hydroxyurea
Sponsors:   Vanderbilt University Medical Center;   Medical College of Wisconsin;   Blood Center of Wisconsin
Recruiting - verified April 2017


Stem Cell Transplantation for Sickle Cell Anemia


Condition:   Sickle Cell Disease
Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Procedure: Stem Cells
Sponsor:   Hackensack University Medical Center
Recruiting - verified January 2017


A Phase II Trial of Regadenoson in Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Regadenoson;   Drug: Placebo
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Boston Children’s Hospital;   La Jolla Institute for Allergy & Immunology;   National Heart, Lung, and Blood Institute (NHLBI);   Washington University School of Medicine;   Children's Hospital Medical Center, Cincinnati;   University of Illinois at Chicago;   Medical College of Wisconsin;   Duke University;   Johns Hopkins University;   Wayne State University;   Baylor College of Medicine;   Children's Hospital & Research Center Oakland
Recruiting - verified August 2016


A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Intervention:   Drug: N-Acetylcysteine
Sponsors:   Bloodworks (Puget Sound Blood Center);   University of Washington
Enrolling by invitation - verified May 2017


Microvascular Blood Flow in Sickle Cell Anemia


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Interventions:   Drug: regadenoson infusion with contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound
Sponsors:   Blood Center of Wisconsin;   Medical College of Wisconsin;   La Jolla Institute for Allergy & Immunology;   University of Illinois at Chicago;   Oregon Health and Science University;   Dana-Farber Cancer Institute
Recruiting - verified July 2016


Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy


Conditions:   Sickle Cell Anemia;   Cerebrovascular Accident
Interventions:   Procedure: Stem cell transplantation;   Procedure: Transfusion program
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified November 2016


Iron Mediated Vascular Disease in Sickle Cell Anemia Patients


Condition:   Sickle Cell Disease
Intervention:  
Sponsor:   Children's Hospital Los Angeles
Active, not recruiting - verified March 2017


State Of The Art Functional Imaging In Sickle Cell Disease


Condition:   Sickle Cell Anemia
Intervention:  
Sponsor:   St. Jude Children's Research Hospital
Completed - verified August 2016


Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease


Condition:   Sickle Cell Disease
Intervention:   Drug: GMI-1070
Sponsor:   Pfizer
Completed - verified May 2013


Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia


Conditions:   Sickle Cell Anemia;   Priapism
Interventions:   Drug: tadalafil;   Drug: placebo
Sponsors:   Johns Hopkins University;   Eli Lilly and Company
Withdrawn - verified September 2016


Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders


Condition:   Sickle Cell Disease
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified January 2017


Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease


Condition:   Sickle Cell Disease
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   Children's Hospital Medical Center, Cincinnati
Active, not recruiting - verified June 2016


L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia


Conditions:   Sickle Cell Anemia;   Thalassemia
Interventions:   Drug: L-glutamine;   Drug: Placebo
Sponsors:   Emmaus Medical, Inc.;   FDA Office of Orphan Products Development
Completed - verified March 2017


Heart Disease in Sickle Cell Anemia


Conditions:   Sickle Cell Anemia;   Pulmonary Hypertension
Intervention:  
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified October 2, 2007


Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease


Condition:   Sickle Cell Anemia
Interventions:   Drug: L-NMMA;   Drug: Sodium Nitrite
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 7, 2015


Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Hydroxyurea;   Drug: L-Arginine;   Drug: Sildenafil
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified December 7, 2015


Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia


Conditions:   Pulmonary Hypertension;   Sickle Cell Anemia;   Sickle Cell Disease
Intervention:  
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 16, 2017


Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 18, 2015

Refine Your Search Advanced Search